Interleukin-17 upregulation participates in the pathogenesis of heart failure in mice via NF-κB-dependent suppression of SERCA2a and Cav1.2 expression

Acta Pharmacol Sin. 2021 Nov;42(11):1780-1789. doi: 10.1038/s41401-020-00580-6. Epub 2021 Feb 15.

Abstract

Interleukin-17 (IL-17), also called IL-17A, is an important regulator of cardiac diseases, but its role in calcium-related cardiac dysfunction remains to be explored. Thus, we investigated the influence of IL-17 on calcium handling process and its contribution to the development of heart failure. Mice were subjected to transaortic constriction (TAC) to induce heart failure. In these mice, the levels of IL-17 in the plasma and cardiac tissue were significantly increased compared with the sham group. In 77 heart failure patients, the plasma level of IL-17 was significantly higher than 49 non-failing subjects, and was negatively correlated with cardiac ejection fraction and fractional shortening. In IL-17 knockout mice, the shortening of isolated ventricular myocytes was increased compared with that in wild-type mice, which was accompanied by significantly increased amplitude of calcium transient and the upregulation of SERCA2a and Cav1.2. In cultured neonatal cardiac myocytes, treatment of with IL-17 (0.1, 1 ng/mL) concentration-dependently suppressed the amplitude of calcium transient and reduced the expression of SERCA2a and Cav1.2. Furthermore, IL-17 treatment increased the expression of the NF-κB subunits p50 and p65, whereas knockdown of p50 reversed the inhibitory effects of IL-17 on SERCA2a and Cav1.2 expression. In mice with TAC-induced mouse heart, IL-17 knockout restored the expression of SERCA2a and Cav1.2, increased the amplitude of calcium transient and cell shortening, and in turn improved cardiac function. In addition, IL-17 knockout attenuated cardiac hypertrophy with inhibition of calcium-related signaling pathway. In conclusion, upregulation of IL-17 impairs cardiac function through NF-κB-mediated disturbance of calcium handling and cardiac remodeling. Inhibition of IL-17 represents a potential therapeutic strategy for the treatment of heart failure.

Keywords: L-type calcium channel; NF-κB; SERCA2a; calcium transient; heart failure; interleukin-17; neonatal cardiac myocytes; transaortic constriction.

MeSH terms

  • Animals
  • Animals, Newborn
  • Calcium Channels, L-Type / biosynthesis*
  • Calcium Channels, L-Type / genetics
  • Cell Line
  • Cells, Cultured
  • Gene Expression
  • Heart Failure / genetics
  • Heart Failure / metabolism*
  • Heart Failure / pathology
  • Humans
  • Interleukin-17 / biosynthesis*
  • Interleukin-17 / deficiency
  • Interleukin-17 / genetics
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • NF-kappa B / biosynthesis*
  • NF-kappa B / genetics
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / biosynthesis*
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / genetics
  • Up-Regulation / physiology*

Substances

  • CACNA1C protein, mouse
  • Calcium Channels, L-Type
  • Il17a protein, mouse
  • Interleukin-17
  • NF-kappa B
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • Atp2a2 protein, mouse